EHS
EHS

Long non-coding RNA MALAT1 expression in patients with gestational diabetes mellitus.

Related Articles

Long non-coding RNA MALAT1 expression in patients with gestational diabetes mellitus.

Int J Gynaecol Obstet. 2018 Feb;140(2):164-169

Authors: Zhang Y, Wu H, Wang F, Ye M, Zhu H, Bu S

Abstract
OBJECTIVE: To monitor the expression of long non-coding RNAs (lncRNAs) and changes in metabolic profiles among patients with gestational diabetes mellitus (GDM).
METHODS: A retrospective case-control study was conducted using data for women treated at a hospital in China between October 8, 2014, and April 15, 2015. Patients diagnosed with GDM using an oral glucose tolerance test at 24-28 weeks of pregnancy (n=50) were included. The control group comprised pregnant women without GDM (n=47). Serum levels of lncRNA MALAT1, lncRNA p21, and lncRNA H19 were assessed using the reverse transcription polymerase chain reaction. Plasma glucose and lipid levels were assessed biochemically.
RESULTS: The expression level of lncRNA MALAT1 was higher among the cases than the controls (P=0.007). Expression of IncRNA MALAT1 among the patients with GDM correlated with both lncRNA p21 (r=0.333, P=0.018) and lncRNA H19 (r=0.314, P=0.030). Levels of triglycerides and total cholesterol differed between the control group and patients with GDM (3.6 ± 2.6 mmol/L vs 3.8 ± 1.5 mmol/L and 6.54 ± 1.30 mmol/L vs 7.40 ± 0.90 mmol/L, respectively; P<0.05). The area under the receiver operating characteristic curve was 0.654 (95% confidence interval 0.543-0.768, P<0.001).
CONCLUSION: Expression of lncRNA MALAT1 could offer a novel biomarker to predict GDM.

PMID: 29110299 [PubMed – indexed for MEDLINE]

EHS
Back to top button